Dentists in Blackwell, OK Accepting Medicare
5 Dentists found. Showing 1 - 5
 Dr. Travis Harold Luke, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1520 S Main St, Blackwell, OK 74631 Phone: 580-262-8420 |
 Michelle Chan, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1520 S Main St, Blackwell, OK 74631 Phone: 864-260-7285 |
Dr. Aaron Martin Neale, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 1520 S Main St, Blackwell, OK 74631 Phone: 918-960-4013 |
Dr. Robert London, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1520 S Main St, Blackwell, OK 74631 Phone: 580-628-7741 |
Eric Scott Hammack, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 119 West Bridge, Blackwell, OK 74631 Phone: 580-363-4245 Fax: 580-363-0082 |
News Archive
Majority of people may endorse use of revenge porn, research finds
Research by psychologists at the University of Kent has found that a majority of people would endorse the use of revenge porn and that those who actually post it have a distinct personality profile.
Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA
Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of life-threatening infectious diseases, announced it has signed an agreement with the Ludwig-Maximilians-University (LMU) of Munich to coordinate a European Union grant for Phase 2 clinical trials of SQ109 in adult pulmonary tuberculosis (TB) in seven sites in Africa.
Findings shed light on the genetic origins of diabetes
Pediatric researchers have found that a gene already implicated in the development of type 2 diabetes in adults also raises the risk of being overweight during childhood. The finding sheds light on the genetic origins of diabetes and may present an avenue for developing drugs to counteract the disease, which has been on the upswing in childhood and adolescence.
Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.
› Verified 2 days ago